Targeting Phage Therapy 2026 Congress in Valencia to Formalize Global Infrastructure for Antibacterial Medicine

International experts meet in June 2026 to scale phage therapy production and establish global regulatory standards for antibacterial medicine.

By: AXL Media

Published: Apr 28, 2026, 5:25 AM EDT

Source: Information for this report was sourced from EurekAlert!

A Strategic Shift Toward Mainstream Phage Deployment

The upcoming Targeting Phage Therapy 2026 Congress in Valencia marks a decisive moment for the medical community as it faces the escalating threat of antimicrobial resistance. The event aims to shift the focus from proving the efficacy of bacteriophages to building the essential clinical and industrial infrastructure required for routine therapeutic use. By bringing together clinicians, regulators, and biotech innovators, the congress seeks to address the logistical barriers that currently prevent phage therapy from being widely accessible. The central challenge remains how to transform these promising scientific insights into validated, deployable medicines that can be integrated into existing healthcare systems.

Harnessing Evolutionary Pressure as a Therapeutic Lever

The opening of the congress will feature a keynote by Benjamin K. Chan of Yale University, who will present a strategy for turning bacterial evolution into a therapeutic advantage. Rather than viewing resistance as an insurmountable obstacle, this approach uses phages to drive bacteria toward evolutionary trade-offs that weaken their pathogenicity. By forcing bacteria to adapt to phage predation, researchers can potentially restore their sensitivity to traditional antibiotics, creating a dual-threat treatment model. This shift in thinking represents a new frontier in the fight against resistant infections, emphasizing the importance of understanding the fundamental biological interactions between phages and their bacterial hosts.

Expanding Applications Beyond Human Clinical Medicine

The scope of the 2026 agenda extends significantly into the realm of animal health and environmental sustainability. Research from institutions such as the University of Nottingham and the University of Aveiro will highlight how phage therapy can be applied to livestock and aquaculture to control infection without relying on antibiotics. These One Health applications are critical for reducing the global burden of antimicrobial resistance, as the health of humans, animals, and ecosystems is deeply interconnected. By exploring piglet health and aquatic disease models, the congress underscores the versatility of phages as a sustainable tool for infection control across multiple industries.